Story continues below

Item 8.01.Other Events.

As previously reported in the Companys Current Report on Form 8-K
filed with the Securities and Exchange Commission (the SEC) on
April 12, 2017, Unilife Corporation (the Company) and its U.S.
subsidiaries filed voluntary petitions in the United States
Bankruptcy Court for the District of Delaware (the Bankruptcy
Court) for relief under Chapter 11 of the United States
Bankruptcy Code, as amended.On May 10, 2017, the Company
announced that as a result of the bankruptcy, the Company intends
to adopt a modified reporting program with respect to its
reporting obligations under the federal securities laws.In lieu
of filing annual reports on Form 10-K and quarterly reports on
Form 10-Q, the Company will file with the SEC a current report on
Form 8-K that will have attached to it the monthly financial
reports required by the Bankruptcy Court.

On June 1, 2017, the Company submitted to the Bankruptcy Court
its monthly financial reports for itself and its U.S.
subsidiaries for the month ended April 30, 2017 (the Monthly
Reports). The Monthly Reports are filed as Exhibit 99.1 to this
Form 8-K and are incorporated herein by this reference.

Cautionary Statement Regarding the Monthly Reports

The Monthly Reports contain financial statements and other
financial information that have not been audited or reviewed by
any independent public accounting firm and may be subject to
future reconciliation or adjustments. The Monthly Reports are in
a format prescribed by applicable bankruptcy laws and should not
be used for investment purposes. The Monthly Reports may not be
indicative of the Companys financial condition or operating
results. Results set forth in the Monthly Reports should not be
viewed as indicative of future results.

Forward-Looking Statements

This report contains forward-looking statements. All statements
that address operating performance, events or developments that
the Company expects or anticipates may or will occur in the
future are forward-looking statements. These forward-looking
statements are based on managements beliefs and assumptions and
on information currently available to the Companys management.
The Companys management believes that these forward-looking
statements are reasonable as and when made. However, you should
not place undue reliance on any such forward-looking statements
because such statements speak only as of the date when made. The
Company does not undertake any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. In addition, forward-looking statements are subject to
certain risks and uncertainties that could cause actual results,
events and developments to differ materially from the Companys
historical experience and the Companys present expectations or
projections. These risks and uncertainties include, but are not
limited to, those described in Item 1A. Risk Factors and
elsewhere in the Companys Annual Report on Form 10-K, those
described from time to time in other reports which the Company
files with the SEC, and other risks and uncertainties.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number


Exhibit 99.1

Monthly Financial Report of Unilife Corporation, et al.
for Month Ending April 30, 2017


Unilife Corporation is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.


UNILIFE CORPORATION (NASDAQ:UNIS) closed its last trading session up +0.0098 at 0.0995 with 772,712 shares trading hands.

An ad to help with our costs